FDA Approves Lyrica Generics
In July 2019, The Food and Drug Administration (FDA) announced their approval of multiple applications for the first generics of pregabalin (Lyrica) for painful peripheral neuropathy and other conditions, including fibromyalgia and shingles.
The approvals for generic versions of Lyrica were extended to Alembic Pharmaceuticals, Alkem Laboratories, Amneal Pharmaceuticals, Dr. Reddy’s Laboratories, InvaGen Pharmaceuticals, MSN Laboratories Ltd., Rising Pharmaceuticals, Inc., Sciegen Pharmaceuticals Inc., and Teva Pharmaceuticals.
Pregabalin is a widely-used medication among those of our patients who experience nerve pain. This announcement demonstrates that the FDA is committed to advancing patient access to lower cost, high-quality generic medicines.